Erin Breard, MD
Family Medicine · Monroe, LANPI 1982048237
Payments from drug & device makers
Across 391 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$950
- Lilly USA, LLC$723
- AstraZeneca$633
- AbbVie$619
- Amgen$601
- Takeda Pharmaceuticals U.S.A., Inc.$469
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,120100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $950 |
| Lilly USA, LLC | 43 | $723 |
| AstraZeneca | 35 | $633 |
| AbbVie(2 entities) | 42 | $619 |
| Amgen(2 entities) | 37 | $601 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $469 |
| Teva Pharmaceuticals USA, Inc. | 31 | $389 |
| Pfizer | 19 | $299 |
| Bayer | 18 | $287 |
| Astellas Pharma US Inc | 9 | $157 |
| Boehringer Ingelheim | 8 | $119 |
| Axsome Therapeutics, Inc. | 5 | $101 |
| Merck | 7 | $89 |
| Idorsia Pharmaceuticals US Inc | 4 | $77 |
| GSK | 4 | $72 |
| Exact Sciences | 4 | $67 |
| Abbott | 3 | $57 |
| Ironwood Pharmaceuticals, Inc | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $49 |
| Genentech USA, Inc. | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Eisai Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$104
How this compares
$6,147 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $122,693 |
| JardianceEmpagliflozin | 69 | $86,279 |
| MounjaroTirzepatide | 78 | $85,891 |
| EliquisApixaban | 56 | $67,357 |
| TrulicityDulaglutide | 43 | $44,720 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $23,729 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $22,647 |
| FarxigaDapagliflozin Propanediol | 24 | $20,904 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $20,730 |
| MyrbetriqMirabegron | 26 | $16,340 |
| KerendiaFinerenone | 11 | $15,895 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $6,467 |
| Atorvastatin Calcium | 348 | $4,742 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,863 |
| Gabapentin | 191 | $3,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $723 | $130,611121 claims |
| Novo NordiskOzempic | $950 | $122,69394 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $119 | $110,00886 claims |
| PfizerEliquis, Paxlovid | $299 | $68,72267 claims |
| GSKTrelegy Ellipta | $72 | $22,64729 claims |
| AstraZenecaFarxiga | $633 | $20,90424 claims |
| Astellas Pharma US IncMyrbetriq | $157 | $16,34026 claims |
| BayerKerendia | $287 | $15,89511 claims |
| AbbVieSynthroid | $619 | $1,90430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Monroe
- Clinton GuilloryMonroe$18.5M
- Thomas DansbyMonroe$169K
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.